Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2025-12-25 @ 3:24 AM
NCT ID: NCT05041205
Eligibility Criteria: Inclusion Criteria: * Chinese healthy male or female * Subjects with skin problems such as skin dullness, skin tone unevenness, skin inelasticity, skin dryness, and wrinkle/fine lines. * Subjects without any other chronic or on treatment diseases * Subjects are voluntary to participate the trial and signed informed consents. * Subjects are voluntary to follow all evaluation criteria Exclusion Criteria: * Subjects have a plan to be pregnant, or are in pregnancy or lactation period; * Not participated any clinical trial or evaluation within nearly 1 month; * Used anti-histamine medication within nearly one week or immunosuppressor within nearly one month * Used any anti-inflammation drugs at test site within nearly two months * Subjects who have any skin diseases (psoriasis, eczema, skin cancer etc.) * Subjects with Type I diabetes * Subjects who currently are receiving asthma or other chronic respiratory diseases treatment * Subjects who are receiving anti-cancer chemotherapy in nearly 6 months * Subjects who have anyother health problem or chronic diseases * Subjects who have externally used Vit A, a-hydroxy acid, salicylic acid, hydroquinone within nearly 3 months or prescription medicines, oral contraceptive within nearly 6 months * Expert or professional person evaluate have other iatrogenic reason may impact the evaluation results
Healthy Volunteers: True
Sex: ALL
Minimum Age: 30 Years
Maximum Age: 55 Years
Study: NCT05041205
Study Brief:
Protocol Section: NCT05041205